Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Efferon CT.
- Who it may be relevant to
- Registry conditions: Myocardial Infarction, Cardiogenic Shock. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Russia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Open Randomized Study on the Efficacy and Safety of Hemoadsorption With Efferon CT in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction
Overview
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Detailed description
Cardiogenic shock (CS) is a state of acute critical tissue hypoperfusion caused by impaired myocardial contractility. It is one of the most serious complications of acute coronary syndrome (ACS), particularly acute myocardial infarction (AMI). Cardiogenic shock develops in approximately 30-40% of ACS patients, with a one-year mortality rate of 50-60%.
Despite advances in modern cardiology-including widespread use of timely revascularization, vasopressors, inotropic agents, and mechanical circulatory support-CS-related mortality remains unacceptably high. Efferent therapy, which modulates the homeostasis of biological fluids (e.g., blood) through physical and chemical methods (filtration, apheresis, sorption), represents a promising approach.
Recent studies on the hemoadsorbent CytoSorb in acute cardiac pathology demonstrated reductions in inflammatory markers (IL-6, lactate), improved hemodynamic stability, and lower 30-day ICU mortality (52% vs. 80% SOFA-predicted). These findings highlight the potential of cytokine adsorption to mitigate systemic inflammation in CS.
The Efferon CT hemoadsorption device, which effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa), may improve outcomes by alleviating CS symptoms and preventing multiple organ dysfunction.
Interventions
- Device Efferon CT
Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoadsorption. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa. The therapy will be performed once no later than 4 hours after the diagnosis of cardiogenic shock. The duration of hemoadsorption is from 4 to 12 hours. The rate of hemoadsorption is from 80 to 150 ml/min. Anticoagulation is systemic (heparin or
Primary outcome measures
- Time to Resolution of Cardiogenic Shock (Days) [Time frame: 1-7 days]
Secondary outcome measures (7)
- Need for vasopressor support [Time frame: 0-72 hours]
- Pulmonary oxygen metabolic function [Time frame: 1-7 days]
- SOFA score [Time frame: 1-7 days]
- Duration of ventilation [Time frame: 1-7 days]
- ICU length of stay [Time frame: 1-7 days]
- Hospital length of stay [Time frame: 1-7 days]
- Incidence and severity of AKI [Time frame: 1-7 days]
Eligibility criteria
Inclusion criteria
- Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
- Stages B - C of cardiogenic shock according to SCAI
- Patient condition allows treatment with Efferon® CT device for at least 4 hours
- SOFA score 12 or less
Exclusion criteria
- Broken-heart syndrome (takotsubo cardiomyopathy)
- Postcardiotomy cardiogenic shock
- Acute myocardial infarction within the last 4 weeks
- Myocarditis
- Cardiac trauma
- Charlson comorbidity index greater than 9 points
- Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)
- Acute pulmonary embolism
- Acute cerebral circulatory collapse
- Transfusion reaction
- Patients on immunosuppressive therapy for cancer and autoimmune diseases
- Pregnancy
- Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Russia · 1 center
- Tomsk NRMC Cardiology Research Institute — Tomsk
Identifiers
NCT: NCT06955936 · efferon-ct-2025-01